ARVN News and Press, Arvinas Inc. From 06/22/19

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

NEW HAVEN, Conn., June 20, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO Prescrip...

The following slide deck was published by Arvinas, Inc. in conjunction with this Read more ...

NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Goldman...

Bayer ( OTCPK:BAYRY ) will launch a joint venture with Arvinas (NASDAQ: ARVN ) aimed at developing protein degraders for crop protection. The partnership, which also includes a target-based pharmaceutical research collaboration, will leverage Arvinas' PROTAC technology with Bayer...

- $110M+ life sciences deal to develop novel PROTAC® candidates for patients with cardiovascular, oncological, and gynecological diseases, and to expand application of PROTAC® degraders to plant health - Bayer and Arvinas to launch a joint venture to develop targeted protein...

BERLIN , MONHEIM, Germany and WHIPPANY, N.J. , June 4, 2019 /PRNewswire/ -- Bayer today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company based in New Haven, Connecticut . The new life science research partnership uniquely leverages the full...

The FDA has granted Fast Track designation to Arvinas' (NASDAQ: ARVN ), lead PROTAC protein degrader, ARV-110, for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed after treatment with two or more systemic therapies. More news...

NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced that its lead PROTAC® protein degrader, ARV-110, has been granted Fast Track designatio...

Arvinas (NASDAQ: ARVN ): Q1 GAAP EPS of -$0.46 in-line. More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...